Santhera Pharmaceuticals reported a doubling of first-half revenue to CHF48.3 million, driven by a 48% rise in sales of Agamree, its treatment for Duchenne muscular dystrophy. Despite a 17% price cut in Germany, volume growth exceeded 50%, with further price reductions expected in 2027. Stifel maintains a 'buy' rating and CHF25 target, forecasting CHF85.1 million revenue in 2026 and CHF104.1 million in 2027, supported by expansion in Europe and strong US sales via Catalyst Pharmaceuticals. Santhera aims for CHF250 million revenue by 2030, with sufficient cash to reach profitability despite upcoming price pressures.
Santhera Pharmaceuticals reported a doubling of first-half revenue to CHF48.3 million. For readers following the health sector, here is Pluang's market snapshot as of Sep 30, 2026 18:13 WIB: out of 100 priced US health stocks, 46 rose and 51 fell. Notable movers include Quest Diagnostics Inc (DGX) at USD 238.50 with a 2.82% increase and 100% buy order activity, BioNano Genomics Inc (BNGO) at USD 1.76 with a 2.02% rise and 92% buy activity, and Citius Pharmaceuticals Inc (CTXR) at USD 0.54 down 2.60% with 97% buy activity. Typical hold times range from 16 to 55 days on Pluang.
Jeff Bezos sold $346 million of Amazon stock on August 3, 2026, coinciding with a peak in Amazon's share price. However, the stock declined about 14% since then, pressured by regulatory concerns, a lawsuit from the FTC and 22 states over advertising ...
Bloom Energy is addressing power supply challenges for AI data centers by providing on-site fuel cell solutions that enable faster deployment. The company reported strong Q2 results with $1.06 billion in revenue, a 166% increase year-over-year, a 17....
Solana (SOL) experienced a 2.01% price decline within one hour, falling to $120 as measured on Binance's spot market. This extended its 24-hour loss to 0.60%. During the same hour, liquidations totaled approximately $2.48 million for long positions a...
OpenAI reported rapid growth with a $70 billion annualized revenue run-rate and 70% sequential growth as of Q3 2026, driven by enterprise adoption of new AI features like Private Intelligence. Despite deep net losses of $38.5 billion in FY25 due to a...
Intel could see significant stock gains if it successfully grows its server processor business and improves manufacturing yields. The company’s advanced packaging technology may add new revenue streams, but sustained profitability depends on strong i...
